KKH Kaufm Nnische Krankenkasse Tender

Contract notice: Conclusion of non-exclusive discount agreements in accordance with section 130a, Paragraph 8 of book v of the social code (sgb v) for the items listed in ii.2.4. Named active substances with the option of concluding in the context of the so-called open house procedure. The commercial health insurance company - KKH (hereinafter referred to as KKH) pursues the goal of concluding discount agreements in accordance with Section 130a (8) SGB V for the following active ingredients (ATC) and, if applicable, dosage forms as part of a so-called "open house procedure" with all suitable pharmaceutical companies: 1. Rivaroxabab (ATC: B01AF01) Subject to uniform contract conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the aforementioned active ingredient. Interested pharmaceutical companies can contact the under l.1. request the participation documents and the contract. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. A contract is concluded with every pharmaceutical company that meets the requirements for participation. There is no exclusivity. Accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. Should the KKH carry out an invitation to tender for exclusive contracts in the form of an open procedure for the active ingredients during the contract period, the contracts concluded as part of this publication will be terminated in accordance with the contractual provisions. This contract is divided into lots: no Time limit for receipt of tenders or requests to participate: Date: 31/12/2022Local time: 09:00 Health